A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

NCT06937619 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer

Interventions

DRUG: Risankizumab

Sponsor

AbbVie